Trial Profile
Open-label, Non-randomized, Phase 2 Study Evaluating Efficacy and Safety of PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Bimiralisib (Primary)
- Indications Lymphoma
- Focus Therapeutic Use
- Sponsors PIQUR Therapeutics
- 08 May 2018 Status changed from recruiting to completed.
- 13 Apr 2017 Planned End Date changed from 1 Dec 2017 to 1 Apr 2018.
- 13 Apr 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Sep 2017.